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In the last few years there has been a growing interest in lung clearance index (LCI), a measure
of lung physiology derived from multiple breath washout tests. This resurgence of interest was
initially driven by the recognition that such assessments were capable of detecting early
airways disease in children, and are more sensitive and easier to perform in this population
than conventional lung function tests [Aurora P, Kozlowska W, Stocks J. Gas mixing efficiency
from birth to adulthood measured by multiple-breath washout. Respir Physiol Neurobiol,
2005;148(1e2):125e39]. With an appreciation of the importance of earlier identification of
airways dysfunction, and prevention of irreversible structural airway changes, methods of
following airways disease in these ‘‘silent years’’ are especially important. LCI has now been
reported in studies involving all age groups, from infants to adults [Lum S, Gustafsson P, Ljung-
berg H, Hulskamp G, Bush A, Carr SB, et al. Early detection of cystic fibrosis lung disease:
multiple-breath washout versus raised volume tests. Thorax, 2007;62(4):341e7; Horsley AR,
Gustafsson PM, Macleod K, Saunders CJ, Greening AP, Porteous D, et al. Lung clearance index
is a sensitive, repeatable and practical measure of airways disease in adults with cystic
fibrosis. Thorax, 2008;63:135e40], and has a narrow range of normal over this wide age range,
making it especially suitable for long-term follow-up studies. In cystic fibrosis (CF) particularly,
there is a pressing need for sensitive and repeatable clinical endpoints for therapeutic inter-
ventions [Rosenfeld M. An overview of endpoints for cystic fibrosis clinical trials: one size does
not fit all. Proc Am Thorac Soc, 2007;4(4):299e301], and LCI has been proposed as an outcomeine, Edinburgh Royal Infirmary, 51 Little France Crescent, Edinburgh EH4 2XU, United Kingdom.
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794 A. Horsleymeasure in future CF gene therapy studies [Davies JC, Cunningham S, Alton EW, Innes JA. Lung
clearance index in CF: a sensitive marker of lung disease severity. Thorax, 2008;63(2):96e7].
This review will consider how LCI is derived, how it differs from conventional lung function
testing, and its applications and limitations.
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lung clearance index (LCI), a measure of lung physiology
derived from multiple breath washout tests. This resur-
gence of interest was initially driven by the recognition that
such assessments were capable of detecting early airways
disease in children, and are more sensitive and easier to
perform in this population than conventional lung function
tests.1 With an appreciation of the importance of earlier
identification of airways dysfunction, and prevention of
irreversible structural airway changes, methods of
following airways disease in these ‘‘silent years’’ are
especially important. LCI has now been reported in studies
involving all age groups, from infants to adults,2,3 and has
a narrow range of normal over this wide age range, making
it especially suitable for long-term follow-up studies. In
cystic fibrosis (CF) particularly, there is a pressing need for
sensitive and repeatable clinical endpoints for therapeutic
interventions,4 and LCI has been proposed as an outcome
measure in future CF gene therapy studies.5
This review will consider how LCI is derived, how it
differs from conventional lung function testing, and its
applications and limitations.Multiple breath washout tests
LCI is derived from Multiple Breath Washout (MBW) tests.
The basic principles behind MBW are relatively simple, and
were first described more than 50 years ago.6 The test
involves following the washout of an inert tracer gas from
the lungs during relaxed tidal breathing. The tracer gas can
be nitrogen that is normally resident in the lungs, washed
out when the subject is switched to breathing 100% oxygen.
Alternatively, it can be an exogenous tracer gas that must
first be washed into the lungs to equilibrium. Each approach
has its own advantages and challenges, but the principle is
the same: namely that the tracer gas should be inert and
neither absorbed nor excreted by the body to anysignificant degree. With each successive breath of the
washout, there is a fall in the peak concentration of
exhaled tracer (Fig. 1).
As shown by hyperpolarised helium MRI studies, airways
disease tends to be patchy.7 Airway narrowing due to
factors such as mucus retention, inflammation and airway
wall structural damage causes unevenness of ventilation.
This unevenness, or ventilation heterogeneity, affects the
overall gas mixing efficiency of the lung, and can be
measured by following the washout of a tracer gas during
tidal breathing. In disease, the washout will take longer to
complete, requiring a greater number of breaths.
A number of different indices of deranged ventilation
can be calculated from the washout tracings, but one of the
most robust and sensitive, and hence one of the most
widely reported, of these is the lung clearance index (LCI).
Derivation of lung clearance index
For calculation of LCI, the washout is deemed completed
when the end-tidal tracer gas concentration has fallen
to 1/40th of the starting concentration. The reason for using
1/40th is largely historical, as this represents the limits of
the linear operating range (2e80%) of the early nitrogen
analysers. However, it has stood the test of time and repre-
sents a workable compromise between ending a washout
too soon (and therefore losing sensitivity) and an excessively
protracted procedure.
Functional residual capacity (FRC) is calculated from
multiple breath washouts from the starting end-tidal frac-
tion of tracer gas (CInit), the final fraction of tracer (CEnd),
and the total volume of tracer gas exhaled up to the end of
the washout (V[Tracer]):
FRCZV½Tracer=ðCInit CEndÞ
LCI is then defined as the cumulative expired volume
(CEV), divided by the FRC:
Figure 1 Typical washout tracing of a healthy adult subject. Flow is shown in the upper trace (expiration upwards), with the
scale on the left hand y-axis. Tracer gas (in this case, 0.2% SF6) concentration is shown in the lower trace e with each successive
breath, there is a fall in peak expiratory SF6 concentration.
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In other words, LCI represents a measure of the number
of times the volume of gas in the lung at the start of the
washout (the FRC) must be turned over in order to wash out
the tracer to the pre-defined endpoint. With increasing
disease severity, LCI increases.
Clinical use of LCI
Because no complex respiratory manoeuvres are required,
MBW tests are especially useful in children, and the
majority of recent studies reflect this. The earliest work on
lung gas mixing was performed using nitrogen washout
apparatus. A number of studies, comparing small numbers
of groups of subjects with different respiratory diseases,
were performed in the 1970se1980s.8e10 The gas analyser
and washout analysis technology used in these studies was
relatively crude and constructed in-house. Although
abnormalities in gas mixing indices were demonstrated in
disease, there was little suggestion that these would be
useful clinical assays. A combination of improved analyser
technology and data analysis software, as well as a general
increased interest in the need for robust infant lung func-
tion techniques, has been a major driving force behind the
recent resurgence of interest in LCI.
In 2003, a Swedish group described the use of a mass
spectrometer to perform washouts using 4% sulphur hex-
afluoride (SF6) as the inert tracer gas.
11 They reported
that LCI was elevated in 43 children with cystic fibrosis
(CF) (aged 3e18 years) compared to 28 healthy controls.
More importantly, they showed that LCI was more sensi-
tive than spirometry, being elevated in 22 of the 33 CF
patients with normal spirometry. A similar system, using
the same technique and analysis software, was subse-
quently established at Great Ormond Street Children’s
Hospital in London. Using this apparatus, Aurora et al.
confirmed the Swedish findings in school age children,12
and then went on to use the technique in younger agegroups.13 In pre-school children LCI was higher in those
patients infected with Pseudomonas aeruginosa, an
important lung pathogen in CF and one that is known to be
associated with a poorer prognosis.14 More recently, the
same group have measured LCI in infants as young as 10
weeks old and showed that LCI was elevated in those with
CF (mean age 41 weeks) compared to age matched
healthy controls.2 Using a different analyser technology
altogether, a third group have reported on LCI in adults
and children with CF.3 The normal range of LCI in the
healthy volunteers in all of these studies was almost
identical, despite differences in subject age, location, and
technology. Cumulatively, these studies have demon-
strated that multiple breath washouts can be performed
in large numbers of subjects in clinical studies, and that
LCI can be reliably and reproducibly measured, even in
young subjects. The group mean coefficient of variation of
intra-visit repeat LCI measurements, a simple measure of
reproducibility, ranged from 7.8% in pre-school children
with CF (mean age 4.4 years), to 3.2% in healthy adults
(mean age 33 years).3,13 Although no association between
age and reproducibility has been described in children,12
our own observations suggest that reproducibility declines
with deteriorating LCI.
Longitudinal studies of LCI are particularly important in
establishing how LCI tracks disease progression. A large
Swiss cohort has been followed between the ages of 6 and
20 years.15 142 children with CF have had at least 4 serial
annual evaluations of conventional lung function (spirom-
etry, specific airway resistance and FRC at plethysmog-
raphy), P. aeruginosa infection status, and LCI (performed
using a nitrogen washout apparatus). They demonstrated
that LCI was the earliest measurement to deteriorate,
followed by FEF50, FVC and finally FEV1. LCI was elevated
in more than half of those with FEV1 within the normal
range. Furthermore LCI continued to increase, along with
pulmonary hyperinflation and trapped gas volume, beyond
the age of 12 years, whereas FEV1 z-scores stabilised. In
subsequent papers derived from the same dataset they
796 A. Horsleyalso showed that LCI was more elevated in those with
ABPA, and that the slope of longitudinal progression of LCI
was greatest in those chronically infected with P. aerugi-
nosa.16 LCI was also the most sensitive discriminator
between groups divided on the basis of chronic and
intermittent P. aeruginosa colonization of the lower
airway.
It is not possible to know exactly what LCI represents at
a histological level, since airway histopathology in subjects
with mild disease is not available. Most of the work pub-
lished in LCI so far has looked at CF, and our understanding
of this disease is that it affects primarily the small airways,
at least initially.17 This, and other evidence, leads us to
believe that LCI is particularly sensitive to small airways
dysfunction. Further support for this came from a study
of CT appearances, spirometry and LCI in 44 children (age
5e19 years) with CF.18 Sensitivity of FEV1 to structural
abnormalities on CT was poor. LCI was the most sensitive
measure of structural lung abnormalities, particularly air
trapping, for which it had a sensitivity of 94%. In addition,
LCI was also elevated in one third of those with a normal CT
score, which may represent the presence of physiological
abnormalities due to disease that is below the limit of
resolution of the CT scanner. Normal LCI in a patient with
CF almost excluded the presence of structural abnormali-
ties on HRCT.
LCI also has a potential role in asthma and wheeze. It is
known that asthma has a number of different phenotypes in
childhood, some of which may be associated with structural
airway wall changes (airway remodelling).19 There is also
evidence from bronchial biopsy studies of structural airway
changes in children with wheeze as young as 3 years old.
This has clinical implications as, in many cases, asthma
symptoms diminish in late childhood but inflammation and
airway remodelling may be progressive in adulthood.20
There is now a recognised need for robust and repeatable
surrogate measures to detect and track early lung function
abnormalities in the presence of progressive airway
remodelling.
Two studies have measured LCI in asthmatic children
with a view to investigating evidence of ventilation
heterogeneity and its response to acute treatment. In the
first of these, Gustafsson reported on LCI and spirometry in
children with asthma and CF.21 He showed that LCI was
elevated in asthma, and fell in response to nebulised
bronchodilator. The CF patients had a similar degree of
impairment in FEV1 to the asthmatics (groups mean FEV1
72% and 77% predicted, respectively), but had significantly
higher LCI, which did not respond to bronchodilators. More
recently, Macleod et al. reported that LCI in a cohort of
children with well-controlled asthma (mean FEV1 z-score
of 1.26) was significantly elevated compared to age
matched healthy controls, although the absolute elevation
in LCI was modest (mean LCI 6.69 in the asthmatics versus
6.24 in controls). Despite adequate preventative treatment
and clinical stability, FEV1 improved significantly following
inhaled salbutamol. LCI did not improve, but remained
significantly higher than controls, indicating evidence of
non-bronchodilator responsive residual airways disease that
was not detected by spirometry. LCI may offer an alterna-
tive method of assessing airway physiology in this and
similar populations.Advantages of LCI
It is the sensitivity to small airways dysfunction that makes
LCI such a valuable measure of airway physiology. Spirom-
etry, essentially a measure of airway resistance at flow
limitation, has long been known to be an insensitive
measure of small airways disease. The small airways (those
less than 2 mm diameter) have a large combined cross-
sectional surface area and therefore have low mean flow
rates and combined resistance. In healthy adults, they
contribute less than 10% of the total airways resistance.22
Considerable structural damage to these airways can
therefore occur before there is any impairment of FEV1.
23
Using hyperpolarised helium MRI to image the distribution
of inhaled helium, it has also been shown that FEV1 is
insensitive to disturbances in ventilation distribution.7 LCI
therefore fills an important gap in our ability to follow
airways disease non-invasively e the so called ‘‘silent
zone’’ between onset of pathology and detection of this
with standard lung function tests.
Several studies have now shown LCI to be considerably
more sensitive to disease than spirometry.3,11e13 The
particular sensitivity of LCI to CF lung disease may reflect
the underlying lung pathology, which is one of uneven small
airways inflammation and obstruction.24 There is growing
interest in the early identification and treatment of lung
disease, and this is particularly true in CF where untreated
disease leads to a progressive and irreversible decline.
Because only tidal breathing is required, LCI is ideal for
use in children. No complex or forced respiratory
manoeuvres are required. The test can therefore be
successfully performed in the majority of those down to
pre-school years,1 though very young children may require
sedation. In infants, the challenges are greater because of
the technical demands on the apparatus, but the demon-
stration that this can be done successfully is an exciting
development in this field.2
A particular problem with other measures of small
airway function, such as mid-expiratory flows and single
breath washout tests, is that they are poorly reproduc-
ible.25 LCI however has good intra-visit reproducibility (with
a coefficient of variation of repeat measurements of around
3e8%3,12), which is as good, or better, than most lung
physiology assessments in the lab.26 Inter-visit reproduc-
ibility is also good in healthy volunteers.3
The range of LCI in normal subjects is remarkably narrow
across a wide age range, and consistent throughout the
various studies.1,3,11e13 Unlike spirometry, it is also unaf-
fected by height or gender. Because it is derived using the
FRC, differences due to physical size are already accounted
for, leaving only the effects of gas mixing. This is especially
important for longitudinal studies, particularly in children.
Since spirometry changes with age, height and gender, it is
normally expressed as a percent predicted. But this means
accepting a wide range of FEV1 which would be considered
‘‘normal’’ for any individual, and the equations most
commonly used to determine normal range change in late
teens.27,28 Use of different prediction equations for
‘‘normality’’ can have profound effects on the measured
rate of decline in ‘‘% predicted’’ values for spirometry.29
These problems are particularly acute when assessing lung
Figure 2 Subject performing a washout. The supply of wash-
in gas (0.2% SF6 in air) is provided by the cylinder in the
background. An Innocor gas analyser is used to measure flow
and SF6 concentration and expiratory volume is displayed to
the subject on a separate screen.
LCI review 797function during the adolescent growth spurt, which itself
may be affected by disease processes (e.g. CF). Normal LCI
however remains unchanged, allowing any deviation to be
easily identified. Although LCI was slightly higher in the
infants, this may be due to differences in protocol (the test
was performed supine) or due to the effects of serial
deadspace.30
Disadvantages of LCI
The test takes much longer to perform than simple
spirometry, and (for an exogenous tracer) requires both
a wash-in and a washout phase. In normal children or those
with mild disease, the entire process takes little more than
5 min, but is conventionally repeated in triplicate and
therefore takes around 15 min to complete. In adults,
a single wash-in and washout may take twice as long. A
good mouthpiece seal is required, and this can be difficult
to sustain for prolonged periods.
The sensitivity of LCI means that, whilst it is a simple
and useful test in those with early airways disease, it is
much less informative and more protracted in those with
significant airflow obstruction. In addition, particularly in
those with severe CF, interventions that reduce the burden
of airway infection and inflammation may open up previ-
ously poorly ventilated lung regions. This may actually
increase the heterogeneity between well and poorly
ventilated units, paradoxically worsening LCI. In these
subjects, spirometry is probably a more useful indicator of
the state of their airways.
Practicalities of measuring LCI
Although well established in a research setting, the tech-
nology required for multiple breath washout assessment is
considerably more complex than it at first appears. Until
recently there have been no commercial apparatus avail-
able, and no universal standards for performing the tests.
Studies so far have therefore relied upon apparatus and
protocols developed in-house. During a nitrogen washout,
the fractional nitrogen and oxygen concentrations alter
during the course of both individual breaths and the
washout as a whole. This alters the viscosity of the expi-
rate, and hence the measured flow, by up to 12%.8 In order
to accommodate this, continuous adjustment of flowmeter
output is required according to the measured nitrogen
concentration. Although this can be done by computer, in
the absence of an off-the-shelf commercial system it
requires individual programming by the user.
In addition, with nitrogen washout systems the contri-
bution of additional body nitrogen excreted during the
lungs may become significant with prolonged washouts,
though is not felt to be significant in normal subjects.31
Sufficient time must be left between washouts for addi-
tional oxygen to be expired or absorbed, and the resting gas
concentrations return to baseline e this is recommended to
be at least 15 min.32
The alternative approach of using an exogenous inert
marker gas requires the subject to first wash in the tracer
until inspiratory and expiratory marker gas concentrations
are equal. The supply of gas is then disconnected and as thesubject breathes room air the marker gas is washed out
from the lungs in the same way as nitrogen is during the
nitrogen washout. This approach relies on the availability of
an inert marker gas, and the two gases that have been used
in previous studies are helium and SF6, although only data
from SF6 washouts have been reported.
1,11e13
The advantages of using a mass spectrometer to follow
SF6 concentrations are that it offers a stable gas signal,
with a rapid analyser response time.1 This has been crucial
in the development of this technology in the assessment of
very young subjects, including infants.2 The mass spec-
trometer also offers the possibility of measuring more than
one gas, so that simultaneous washouts of gas species with
different diffusion coefficients (helium and SF6) can be
performed in order to explore the effects of diffusion on
gas mixing.33,34
Mass spectrometers however are costly and tempera-
mental devices, and a separate supply of tracer gas is
required (unlike the nitrogen washout system which can use
the hospitals’ piped oxygen). An alternative photoacoustic
gas analyser, known as Innocor, has also been employed
to measure LCI in washouts from 0.2% SF6.
3 This has the
advantages of being considerably more compact and robust
than the mass spectrometer, but cannot measure the same
range of different gases and has a slower analyser response
time which may limit its use to school age children and
older. Innocor also requires modification and custom-built
software in order to use it in this way3 (see Fig. 2).
A third system has also been used, based upon an
ultrasonic flowmeter to measure both flow and molar mass
(a measure of gas density) (ndd medizintechnik, Berne,
Switzerland).35 This is used in the mainstream position,
which reduces apparatus deadspace and response time
(both important for use in very young subjects with low
tidal volumes and high respiratory rates). However the gas
density is also affected by heat, moisture and CO2 content
of the gas sample, so complex experimentally derived
algorithms are required to correct for this, and dynamic
798 A. Horsleychange in these variables remains difficult to correct
for.36,37
At the moment, MBW tests remain restricted to a small
number of laboratories, where they are used primarily as
research tools. However, the simplicity and reproducibility
of the technique make it especially useful for long-term
follow-up in children and a few units have successfully
integrated these measurements into their annual assess-
ments of CF lung function.15,38 In addition, LCI is now also
being worked up for use as a possible endpoint in trials of
CF gene therapy.5 There is now considerable interest in
using MBW to assess airways function, and progression, in
a range of other diseases.
Recognising the importance of clear guidelines in
assisting development of this technology, the European
Respiratory Society and American Thoracic Society are
currently preparing guidelines on the performance and
analysis of multiple breath washouts. It is hoped that this
will standardize the procedures used in different units.
Clear guidance should also permit and encourage manu-
facturers to develop commercial apparatus for the
measurement of LCI. If this happens, it will allow units
without specialist technical and computing support to
access the technology, and should further facilitate prog-
ress in this emergent field.Acknowledgements
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